AGAMREE® (vamorolone) is a first-in-class drug that works similarly to corticosteroids (anti-inflammatory medications used to help maintain muscle strength). AGAMREE® aims to retain the beneficial anti-inflammatory and muscle-strengthening aspects of corticosteroids, while decreasing some of the undesirable side effects (bone fragility, stunted growth, insulin resistance, mood changes, delay of puberty and others).
AGAMREE® (vamorolone) is a dissociative steroid indicated for individuals diagnosed with Duchenne muscular dystrophy from age 2 years and older. For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.
This program is sponsored by Santhera Pharmaceuticals and has been partially funded by Parent Project Muscular Dystrophy.
|A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
|A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
|A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
OPEN LABEL EXTENSION
|Long-term Extension Study to Assess Vamorolone
Santhera Pharmaceuticals Presents at the PPMD 2021 Virtual Annual Conference
Pre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library
Santhera Pharmaceuticals Duchenne Drug Development Update
Santhera Pharmaceuticals joined Parent Project Muscular Dystrophy (PPMD) for a webinar on March 24, 2021 to provide an update to the community about the investigational therapy vamorolone, the use of steroids to treat Duchenne muscular dystrophy, clinical trials for vamorolone, and development timelines.
ReveraGen Presents at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library
Paula Clemmons, MD Presents at the PPMD 2019 Annual Conference
Webinar: Vamorolone Clinical Trials in DuchenneOn January 30, 2019, ReveraGen joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the vamorolone drug development program for Duchenne, including results showing improved muscle function in completed clinical trials in 48 Duchenne boys, and a description of an ongoing clinical trial of 120 Duchenne boys that is accepting new patients at 30 sites internationally.
ReveraGen Presents at the PPMD 2018 Annual Conference
Webinar: Vamorolone (VBP15) Clinical Trials in DuchenneOn January 18, 2017, PPMD was joined by ReveraGen BioPharma for a webinar discussion on vamorolone (VBP15) clinical trials in Duchenne.